MAKO Surgical Corp. Names Charles W. Federico to Board of Directors

admin MAKO Surgical, Portfolio News

FORT LAUDERDALE, Fla. (June 6, 2007) – MAKO Surgical Corp., a developer of
minimally invasive, robotic-enabled techniques for knee surgery, announced today that
Charles W. Federico has been named to the company’s Board of Directors, effective June
5.

Federico has more than 32 years experience in the medical device industry and most
recently served as Group President and Chief Executive Officer of Orthofix N.V., a
recognized leader in minimally invasive orthopedic and trauma surgical devices.
Federico remains a director at Orthofix and also serves as a trustee on the prestigious
Orthopaedic Research and Education Foundation.

“We are extremely pleased to have Charles Federico join our Board of Directors,” said
MAKO Surgical Corp. President and CEO Maurice R. Ferré, M.D. “His knowledge and
reputation are second to none within the orthopedic medical device industry, and we feel
he will bring tremendous value and insights to MAKO.”

Prior to joining Orthofix in 1996, Federico was President of Smith & Nephew
Endoscopy, formerly known as Dyonics, Inc, a top arthroscopic surgical instrumentation
company. He also served as Vice President, Director of Marketing and General Manager
of Dyonics and has held numerous management and marketing positions with General
Foods Corporation, Puritan Bennett Corporation and LSE Corporation. In addition, he
currently serves on the boards of SRI/Surgical Express, Inc. and BioMimetic
Therapeutics, Inc.

About MAKO Surgical Corporation

MAKO Surgical Corp. is a privately held, emerging orthopedic medical device company
developing advanced solutions for less invasive knee surgery. Founded in November
2004, the company has developed and released the MAKO Haptic Guidance System™
(HGS™). This FDA-cleared, physician-interactive robotic system allows surgeons to
provide an innovative tissue-sparing bone resurfacing therapy called MAKOplasty™ to a
large, yet significantly underserved patient population suffering from early to mid stage
degenerative joint disease of the knee. MAKOplasty™ empowers orthopedic surgeons to
improve patient outcomes, shorten recovery time and enhance post-operative lifestyle.
To date, the company has performed more than fifty MAKOplasty™ procedures in
support of unicondylar knee arthroplasty. MAKO’s proprietary technology is protected
by more than 250 patents and patent applications in the areas of robotics, haptics, robotic
surgery, image guided surgical navigation, implants and materials. For more information,
please visit www.makosurgical.com.